Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
Rhea-AI Summary
Theravance Biopharma (NASDAQ: TBPH) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 8, 2025, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) on the same day.
Participants can join via telephone by dialing (800) 715-9871 from the US or (646) 307-1963 internationally, using Conference ID 3369474. The webcast will be accessible through the Investors section of Theravance Biopharma's website and will remain available for replay until June 7, 2025.
Positive
- None.
Negative
- None.
DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day.
Conference Call Information
To participate in the live call by telephone, please dial (800) 715-9871 from the US or (646) 307-1963 for international callers, using the Conference ID 3369474. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations.
A replay of the webcast will be available on Theravance Biopharma's website for 30 days through June 7, 2025.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-first-quarter-2025-financial-results-on-may-8-2025-302436877.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma (TBPH) release Q1 2025 earnings?
How can investors join TBPH's Q1 2025 earnings call?
What time is Theravance Biopharma's Q1 2025 earnings call?
How long will TBPH's Q1 2025 earnings call replay be available?
